Organon & Co. (OGN) — Moat, Quality & Fair Value

Organon & Co. (OGN) has a None economic moat and a quality score of 52/100. It operates in the Health Care sector.

Industry: Pharmaceuticals · Health Care

Market share (2025): 0.3% of Specialty, generic & consumer pharma

Economic moat: None. A none moat indicates no clear structural protection from competition. Learn more about how we classify moats in our guide to economic moats.

Quality score: 52/100. This score combines seven weighted pillars — returns on capital, margin strength, cash generation, financial health, durability, management, and moat & position. See how the quality score works.

The three-tier owner-earnings fair value estimate, price & fair-value chart, financial statements, and complete management evaluation for OGN are available in the MoatScope app (14-day free trial, no card required). New to the framework? Start with the MoatScope guide.

Interactive analysis ↓

MoatScope

Stock Quality, Tracked.

Loading universe…

Screen every US stock through the lens of competitive advantage.

MoatScope rates 5,800+ US-listed stocks and plots more than 3,000 of them on a Quality × Valuation grid. Every rated company gets a moat rating (Wide, Narrow, or None) and a 0–100 quality score; more than 3,000 also get a three-tier owner-earnings fair value estimate.

Wide / Narrow / None moat ratings on every analyzed stock, with full reasoning.
Seven-pillar quality score: profitability, capital efficiency, balance sheet, growth consistency, margin stability, cash conversion, capital allocation.
Owner-earnings fair value in three tiers (Conservative, Base, Optimistic).
Quality × Valuation scatter plot — find high-quality businesses trading below fair value at a glance.
SEC EDGAR-driven data — fundamentals come direct from XBRL filings.

About MoatScope · User guide · Blog · Pricing · FAQ